TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03229499
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
Study: NCT01484340
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The nicotine patch be given in three phases:~* 2 weeks of patches at enrollment~* 6 weeks of patches at two-week follow-up visit~* 2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg.
Study: NCT02698293
Drug: Gliolan
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally, 40 mg/kg 4-6 hours prior to light application
Study: NCT01134523
Drug: Epirubicin, CTX, Paclitaxel
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
Study: NCT01134523
Drug: Epirubicin, Paclitaxel
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
Study: NCT01214278
Drug: rTG
Normalized name: RTG
DrugBank: Ezogabine (DB04953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
Study: NCT01214278
Drug: KPL
Normalized name: Immunoglobulin G4 [222-proline], anti-(human CD40 antigen) (human-Mus musculus monoclonal KPL-404 γ4-chain), disulfide with human-Mus musculus monoclonal KPL-404 κ-chain, dimer
DrugBank: Abiprubart (DB19333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
Study: NCT02696798
Drug: Ixekizumab
Normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered SC
Study: NCT03189706
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg/m\^2/day IV will be administered from day 1-5
Study: NCT03189706
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (given concurrently with Irinotecan) 150mg/m\^2/day orally
Study: NCT02664493
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
Study: NCT04184141
Drug: Hydroxyzine Hydrochloride
Normalized name: hydroxyzine hydrochloride
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyroxyzine hydrochloride is given to the patient one hour before surgery.
Study: NCT04184141
Drug: Alprazolam tablet
Normalized name: Alprazolam Tablets
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprozolam is given to the patient one hour before surgery.
Study: NCT04131426
Drug: Remune
Normalized name: Remune
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
Study: NCT01750983
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group.
Study: NCT01750983
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group.
Study: NCT03189706
Drug: GM-CSF
Normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250mcg/m2/day SC will be administered on days 6-10
Study: NCT00216502
Drug: galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02314013
Drug: Cephalosporin + Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
Study: NCT00941343
Drug: Alfuzosin (XATRAL® - SL770499)
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
Study: NCT02920658
Drug: NAVS Naphthalan
Normalized name: naphthalene
DrugBank: 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid (DB01734)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02920658
Drug: 0.05% Betamethasone dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01584934
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
Study: NCT00154102
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab intravenous infusion of 400mg/m\^2 for the first infusion then weekly intravenous infusion of 250mg/m\^2. Number of Cycles: until progression or unacceptable toxicity develops
Study: NCT02787278
Drug: SP-8203 High dose
Normalized name: high-density polyethylene
DrugBank: SP-8203 (DB11670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
Study: NCT02787278
Drug: SP-8203 Low dose
Normalized name: ethinyl estradiol
DrugBank: SP-8203 (DB11670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
Study: NCT02218164
Drug: Pegylated Interferon alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
Study: NCT02218164
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m\^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
Study: NCT04183881
Drug: Brodalumab 210mg SC
Normalized name: brodalumab
DrugBank: Brodalumab (DB11776)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 210 mg, subcutaneous dosing, every 2 weeks
Study: NCT00428415
Drug: Tesofensine
Normalized name: Tesofensine
DrugBank: Tesofensine (DB06156)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02448771
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02448771
Drug: Bazedoxifene
Normalized name: Bazedoxifene
DrugBank: Bazedoxifene (DB06401)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01691248
Drug: fidaxomicin
Normalized name: Fidaxomicin
DrugBank: Fidaxomicin (DB08874)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
Study: NCT00513214
Drug: XOMA 052
Normalized name: XomaZyme 791
DrugBank: XomaZyme-791 (DB17216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
Study: NCT04934618
Drug: Carelizumab Combined With Irinotecan and Apatinib
Normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three-drug regimen was used in second-line treatment of Advanced gastric cancer
Study: NCT00336908
Drug: a combination of MCT, LCT , and Fish Oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01265056
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg\* daily.~Study day 8-11: 800mg TID 2400mg\* daily \[Optional increase to 2400 if pain scores are still 4 on NRS\]~Study day 11: 1200mg TID 3600mg\* daily \[Optional increase to 3600 if pain scores are still \>4 on NRS\]~\* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation.
Study: NCT00867880
Drug: IVIb
Normalized name: PEMIVIBART
DrugBank: Pemivibart (DB18720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
Study: NCT01669538
Drug: Galantamine
Normalized name: Galantamine
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00379340
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00379340
Drug: Vincristine Sulfate Liposome
Normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00096395
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00096395
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02518113
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT03443778
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marcaine 0.5% Injectable Solution
Study: NCT03443778
Drug: Bupivacaine 0.5% , Dexamethasone
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.5% , Dexamethasone
Study: NCT00242216
Drug: ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Study: NCT00242216
Drug: ritonavir-boosted fosamprenavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
Study: NCT00004037
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00818480
Drug: YM155
Normalized name: Sepantronium bromide
DrugBank: Sepantronium (DB17062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous infusion
Study: NCT00990886
Drug: Oxybutynin chloride
Normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg once daily for 12 weeks
Study: NCT04341090
Drug: Apatinib Mesylate
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of apatinib mesylate after high-fat meal, low fat meal and fast
Study: NCT00658528
Drug: Rabeprazole sodium
Normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
Study: NCT00658528
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
Study: NCT03665545
Drug: IMA950/Poly-ICLC
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMA950 mixed with Poly-ICLC administered subcutaneously
Study: NCT03665545
Drug: IMA950/Poly-ICLC and pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
Study: NCT01067690
Drug: Indinavir in association with Vinblastina +/- Bleomicina
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
Study: NCT00660699
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00660699
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00180050
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00593008
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
Study: NCT00593008
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously every other week of each 28-day cycle.
Study: NCT00876421
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4mg / 12 weeks
Study: NCT00876421
Drug: ONO-8539
Normalized name: ONO-8539
DrugBank: ONO-8539 (DB15325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose / 12 weeks
Study: NCT03962829
Drug: mCPP
Normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy participants administrate one capsule of mCPP (30mg)
Study: NCT00146471
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1500-2000 mg daily add-on or Placebo Diazepam as needed
Study: NCT00876421
Drug: ONO-8539
Normalized name: ONO-8539
DrugBank: ONO-8539 (DB15325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium dose / 12 weeks
Study: NCT01117610
Drug: Ropivacaine (epidural injection)
Normalized name: ropivacaine Injection
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
Study: NCT00876421
Drug: ONO-8539
Normalized name: ONO-8539
DrugBank: ONO-8539 (DB15325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: higher dose / 12 weeks
Study: NCT01055964
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03352349
Drug: Terlipressinum
Normalized name: Terlipressinum
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
Study: NCT00106197
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
Study: NCT03320057
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
Study: NCT04071600
Drug: Neuropeptide Y
Normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal
Study: NCT00455052
Drug: XMT-1001
Normalized name: XMT-1001
DrugBank: XMT-1001 (DB06069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
Study: NCT02456532
Drug: Zolpidem CR
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: six months of nightly zolpidem
Study: NCT02456532
Drug: Eszopiclone
Normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01000337
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
Study: NCT01000337
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
Study: NCT04017962
Drug: Letermovir Pill
Normalized name: letermovir Pill
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks. Patients receiving oral medication will be administered a pill diary for drug compliance purposes. This will be administered and reconciled in clinic.
Study: NCT00056147
Drug: denufosol tetrasodium (INS37217)
DrugBank: Denufosol (DB04983)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01762787
Drug: Cantharidin solution
Normalized name: cantharidin Topical Solution
DrugBank: Cantharidin (DB12328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
Study: NCT01762787
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
Study: NCT00717093
Drug: Varenicline Tartrate
Normalized name: Varenicline tartrate
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
Study: NCT00527501
Drug: Travoprost/brinzolamide
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02606448
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local infiltration of liposomal bupivacaine
Study: NCT02606448
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivicaine was used in all femoral nerve blocks
Study: NCT02400333
Drug: Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water
Normalized name: Ticagrelor Tablets
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg single dose
Study: NCT02400333
Drug: Ticagrelor OD tablet (90 mg single dose) administered without water
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg single dose
Study: NCT02400333
Drug: Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg single dose
Study: NCT02400333
Drug: Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90 mg single dose
Study: NCT00875875
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
Study: NCT02122172
Drug: afatinib dimaleate
Normalized name: afatinib dimaleate
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT04151459
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Use Metformin for 3 months to treat PCOS